Glenmark Pharmaceuticals Tuesday said it has received final approval from the US health regulator for Fluocinolone Acetonide Oil, used to treat eczema of the ear.
Glenmark Pharmaceuticals Inc, USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for Fluocinolone Acetonide Oil, 0.01 per cent (ear drops), a generic version of DermOtic Oil, 0.01 per cent of Hill Dermaceuticals, Inc," the company said in a BSE filing.
Quoting IQVIA sales data for the 12 month period ending October 2018, Glenmark said, the DermaOtic Oil, 0.01 per cent market achieved annual sales of approximately $18.1 million.
The company's current portfolio consists of 146 products authorised for distribution at the US marketplace and 54 abbreviated new drug applications (ANDAs) pending approval with the USFDA.
The company's stock was trading at Rs 686.30 apiece, up 0.42 per cent, on the BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)